

# Treatment with INCB039110 resulted in clinically meaningful symptom relief, modest spleen volume reduction, and limited myelosuppression in patients with myelofibrosis




Open-label phase II study



Patients with intermediate- or high-risk MF + platelet count  $\geq 50 \times 10^9/L$



INCB039110, a potent and selective oral JAK1 inhibitor



	Week		100 mg twice-daily 10 patients	200 mg twice-daily 45 patients	600 mg once-daily 32 patients
Treatment completed	24		50.0%	64.4%	68.8%
≥50% reduction in total symptom score achievement	12	Primary point	20.0%	35.7%	32.3%
	24	End point	20.0%	28.6%	35.5%
Median spleen volume reductions	12	End point		14.2%	14.5%
	24	End point		17.4%	17.1%